Document text
Principal Investigator: Tyler Nelson Starr
Organization: FRED HUTCHINSON CANCER CENTER
Fiscal Year: 2022
Award: $128,574
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
SARS-related coronaviruses (also known as sarbecoviruses) circulate in bat reservoirs, but two human
spillovers in the past 20 years—SARS-CoV-1 in 2002 and SARS-CoV-2 in 2019—have caused globally
devastating outbreaks. The emergence of SARS-CoV-2 from a previously unknown bat lineage highlights the
pressing need to trace the evolutionary origins of viral properties that enable human spillover and develop
therapeutic reagents that can broadly inhibit infection by diverse, potentially unsampled sarbecovirus lineages.
Sarbecovirus zoonosis depends in part on the evolution of viruses to interact with ACE2 receptors on the
surface of human and potential intermediate hosts’ cells, mediated by the viral spike receptor-binding domain
(RBD). The RBD is also a key component to therapeutic control of SARS-CoV-2 and presumably other
sarbecoviruses, as it is the target of the most potently neutralizing antibodies, including those in clinical
development and in polyclonal human sera. Although I and others have begun surveying the impacts of
mutations within SARS-CoV-2 itself on important biochemical phenotypes including binding to ACE2 receptor
and antiviral antibodies, these studies have only limited utility in understanding the broader evolution of
sarbecovirus RBDs, which exhibit considerable divergence in sequence and function.
To characterize sarbecovirus functional and antigenic evolution, I propose to combine high-throughput protein
binding experiments with computational evolutionary analyses, functional virology, and biochemistry:
1. I will profile the ACE2-binding specificities of all known sarbecovirus RBDs and their evolutionary
precursors. I hypothesize that the ability to bind ACE2, including the human ACE2 ortholog, is more
evolutionarily and geographically widespread than previously appreciated.
2. I will systematically characterize how diverse RBD mutations affect ACE2-binding phenotypes. I
hypothesize that human ACE2 binding is an easily evolvable trait in sarbecovirus lineages where it has not
been previously considered. I also hypothesize that divergence among sarbecovirus lineages shifts the genetic
and biochemical determinants of ACE2 binding over evolutionary time.
3. I will identify RBD epitopes that are susceptible to broad pan-sarbecovirus antibody binding. By
determining the relationship between breadth and other antibody properties across RBD epitopes, I highlight
key features to target in the design of next-generation pan-sarbecovirus vaccines and antibody therapeutics.
Identification of the evolutionary and biochemical basis for key sarbecovirus features enhances viral
surveillance and therapeutic development, preparing for or even preventing future sarbecovirus spillovers. The
new experimental expertise, broader training and mentorship, and research systems developed in this work will
enable me to achieve my goal of leading an academic lab studying protein evolution at the host-virus interface.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><Address><Affect><Affinity><Amino Acids><Antibodies><Antigenic Determinants><Antigenic Diversity><Assay><Bats><Binding><Binding Determinants><Binding Proteins><Bioassay><Biochemical><Biochemistry><Biologic Assays><Biological Assay><Biological Chemistry><Biophysics><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><Cell Body><Cells><Chiroptera><CoV-2><CoV2><Disease Outbreaks><Epidemic><Epitopes><Evolution><Exhibits><Future><Genetic><Genetic Alteration><Genetic Change><Genetic defect><Genetics-Mutagenesis><Geography><Goals><Health><Human><Immunity><Infection><Infection prevention><Ligand Binding Protein><Ligand Binding Protein Gene><Maps><Measurement><Measures><Mediating><Mentorship><Methods><Modern Man><Modernization><Molecular><Molecular Interaction><Mutagenesis><Mutagenesis Molecular Biology><Mutation><Ortholog><Orthologous Gene><Outbreaks><Phase><Phenotype><Phylogeny><Population><Position><Positioning Attribute><Preparedness><Prevent infection><Process><Property><Protein Binding><Proteins><Readiness><Reagent><Receptor Protein><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sarbecovirus><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Site><Specificity><Surface><Survey Instrument><Surveys><System><Techniques><Therapeutic><Therapeutic antibodies><Time><Training><Vaccines><Variant><Variation><Viral><Viral Antibodies><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Work><Wuhan coronavirus><Yeasts><Zoonoses><Zoonotic><Zoonotic Infection><aminoacid><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral antibody><antibody engineering><antiviral antibody><biophysical analysis><biophysical foundation><biophysical principles><biophysical sciences><biophysical studies><bound protein><clinical development><combinatorial><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><design><designing><experiment><experimental research><experimental study><genome mutation><hCoV19><human pathogen><molecular recognition><mutant><mutation scanning><mutation screening><nCoV2><neutralizing antibody><next generation><novel><preference><prevent><preventing><prospective><receptor><receptor binding><receptor bound><reconstruction><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><systems research><therapeutic agent development><therapeutic development><tool><trait><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine induced antibodies><vaccine-induced antibodies><virology><virus protein>